RegeneRx provides more clarity, insight into move from heart to eye focus
This article was originally published in Scrip
Executive Summary
After RegeneRx Biopharmaceuticals' Phase II trial of RGN-352, an injectable formulation of Thymosin beta-4 (TB-4), in treating heart attacks came to a screeching halt last month due to manufacturing concerns, the company made a dramatic shift to now focus on its investigational dry eye syndrome drug RGN-259, a sterile, preservative-free topical eye drop formulation of TB-4.